Certifect

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

fipronil, amitraz, (S)-methoprene

Available from:

Merial

ATC code:

QP53AX65

INN (International Name):

fipronil / amitraz / (S)-methoprene

Therapeutic group:

Psi

Therapeutic area:

Ectoparasiticides za lokalno uporabo, vključno. insekticidi

Therapeutic indications:

Zdravljenje in preprečevanje infestations v psov s klopi (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum in Amblyomma maculatum) in bolhe (Ctenocephalides felis in Ctenocephalides canis). Zdravljenje napadov žvečilnih ušes (Trichodectes canis). Preprečevanje onesnaženosti z bolhami z bolečino z zaviranjem razvoja vseh nezrelih stadij bolh. Izdelek se lahko uporablja kot del strategije zdravljenja za nadzor alergijskega dermatitisa. Izločanje bolh in klopov v 24 urah. Eno zdravljenje preprečuje nadaljnje infestacije pet tednov klopov in do pet tednov z bolhami. Zdravljenje posredno zmanjšuje tveganja za prenos klopi prenosljivih bolezni (udarci babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis in borreliosis) iz okuženih klopov za štiri tedne.

Product summary:

Revision: 5

Authorization status:

Umaknjeno

Authorization date:

2011-05-06

Patient Information leaflet

                                Zdravilo nima veā dovoljenja za promet
B. NAVODILO ZA UPORABO
19
Zdravilo nima veā dovoljenja za promet
NAVODILO ZA UPORABO
(Škatla s 3 merilnimi kapalkami)
CERTIFECT 67 MG/ 60,3 MG/ 80 MG KOŽNI NANOS, RAZTOPINA ZA PSE 2–10
KG
CERTIFECT 134 MG/ 120,6 MG/ 160 MG KOŽNI NANOS, RAZTOPINA ZA PSE
10–20 KG
CERTIFECT 268 MG/ 241,2 MG/ 320 MG KOŽNI NANOS, RAZTOPINA ZA PSE
20–40 KG
CERTIFECT 402 MG/ 361,8 MG/ 480 MG KOŽNI NANOS, RAZTOPINA ZA PSE
40–60 KG
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA
SPROSTITEV SERIJE V EGP, ČE STA RAZLIČNA
Imetnik dovoljenja za promet z zdravilom
MERIAL
29, avenue Tony Garnier
FR-69007 Lyon
Francija
Izdelovalec, odgovoren za sprostitev serije:
MERIAL
4, Chemin du Calquet
FR-31000 Toulouse Cedex
Francija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
CERTIFECT 67 mg/ 60,3 mg/ 80 mg kožni nanos, raztopina za pse 2-10 kg
CERTIFECT 134 mg/ 120,6 mg/ 160 mg kožni nanos, raztopina za pse
10-20 kg
CERTIFECT 268 mg/ 241,2 mg/ 320 mg kožni nanos, raztopina za pse
20-40 kg
CERTIFECT 402 mg/ 361,8 mg/ 480 mg kožni nanos, raztopina za pse
40-60 kg
3.
NAVEDBA ZDRAVILNIH UČINKOVIN IN DRUGIH SESTAVIN
Kožni nanos, raztopina
Bistra raztopina jantarne do rumenkaste barve.
Enkratni odmerek (merilna kapalka z dvema razdelkoma) vsebuje:
CERTIFECT kožni nanos,
raztopina
Volumen odmerka
(ml)
Fipronil
(mg)
(S) metopren
(mg)
Amitraz
(mg)
psi 2-10 kg
1,07
67,0
60,3
80,0
psi 10-20 kg
2,14
134,0
120,6
160,0
psi 20-40 kg
4,28
268,0
241,2
320,0
psi 40-60 kg
6,42
402,0
361,8
480,0
Pomožne snovi, nujne za pravilno dajanje: butilhidroksianizol (0,02
%) in butilhidroksitoluen
(0,01 %).
20
Zdravilo nima veā dovoljenja za promet
4.
INDIKACIJE
Zdravljenje in preprečevanje infestacije s klopi pri psih (
_Ixodes ricinus, Dermacentor reticulatus, _
_Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis,
Haemaphysalis elliptica, _
_Haemaphysalis longicornis, Amblyomma americanum _
in
_Amblyomma maculatum) _
in bo
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Zdravilo nima veā dovoljenja za promet
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
1
Zdravilo nima veā dovoljenja za promet
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
CERTIFECT 67 mg/ 60,3 mg/ 80 mg kožni nanos, raztopina za pse 2-10 kg
CERTIFECT 134 mg/ 120,6 mg/ 160 mg kožni nanos, raztopina za pse 10
-20 kg
CERTIFECT 268 mg/ 241,2 mg/ 320 mg kožni nanos, raztopina za pse 20 -
40 kg
CERTIFECT 402 mg/ 361,8 mg/ 480 mg kožni nanos, raztopina za pse 40 -
60 kg
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Zdravilne učinkovine:
Enkratni odmerek vsebuje:
CERTIFECT kožni nanos,
raztopina
Volumen odmerka
(ml)
Fipronil
(mg)
(S)-metopren
(mg)
Amitraz
(mg)
psi 2-10 kg
1,07
67
60,3
80
psi 10-20 kg
2,14
134
120,6
160
psi 20-40 kg
4,28
268
241,2
320
psi 40-60 kg
6,42
402
361,8
480
Pomožne snovi:
Butilhidroksianizol (0,02 %)
Butilhidroksitoluen (0,01 %)
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Kožni nanos, raztopina.
Bistra raztopina jantarne do rumenkaste barve.
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Psi
4.2
INDIKACIJE ZA UPORABO PRI CILJNIH ŽIVALSKIH VRSTAH
Zdravljenje in preprečevanje infestacije s klopi pri psih (
_Ixodes ricinus, Dermacentor reticulatus, _
_Rhipicephalus sanguineus, Ixodes scapularis, Dermacentorvariabilis,
Haemaphysalis elliptica, _
_Haemaphysalis longicornis, Amblyomma americanum _
in
_Amblyomma. maculatum) _
in bolhami
_(Ctenocephalides felis _
in
_Ctenocephalides canis)._
Zdravljenje infestacij z zajedavskimi ušmi (
_Trichodectes canis_
).
Preprečevanje kontaminacije okolice z bolhami z inhibicijo razvoja na
vseh razvojnih stopnjah bolh.
Zdravilo je lahko del zdravljenja alergijskega dermatitisa, ki ga
povzročijo bolhe (FAD). Eliminacija
bolh in klopov v 24 urah. Enkratno zdravljenje 5 tednov preprečuje
infestacije s klopi in do 5 tednov
infestacije z bolhami.
2
Zdravilo nima veā dovoljenja za promet
Zdravljenje posredno 4 tedne zmanjšuje tveganje za prenos s klopi
prenosljivih bolezni (babezioza
psov, monocitna erlihioza, granuloci
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-07-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-07-2018
Public Assessment Report Public Assessment Report Bulgarian 27-07-2018
Patient Information leaflet Patient Information leaflet Spanish 27-07-2018
Public Assessment Report Public Assessment Report Spanish 27-07-2018
Patient Information leaflet Patient Information leaflet Czech 27-07-2018
Public Assessment Report Public Assessment Report Czech 27-07-2018
Patient Information leaflet Patient Information leaflet Danish 27-07-2018
Public Assessment Report Public Assessment Report Danish 27-07-2018
Patient Information leaflet Patient Information leaflet German 27-07-2018
Public Assessment Report Public Assessment Report German 27-07-2018
Patient Information leaflet Patient Information leaflet Estonian 27-07-2018
Public Assessment Report Public Assessment Report Estonian 27-07-2018
Patient Information leaflet Patient Information leaflet Greek 27-07-2018
Public Assessment Report Public Assessment Report Greek 27-07-2018
Patient Information leaflet Patient Information leaflet English 27-07-2018
Public Assessment Report Public Assessment Report English 27-07-2018
Patient Information leaflet Patient Information leaflet French 27-07-2018
Public Assessment Report Public Assessment Report French 27-07-2018
Patient Information leaflet Patient Information leaflet Italian 27-07-2018
Public Assessment Report Public Assessment Report Italian 27-07-2018
Patient Information leaflet Patient Information leaflet Latvian 27-07-2018
Public Assessment Report Public Assessment Report Latvian 27-07-2018
Patient Information leaflet Patient Information leaflet Lithuanian 27-07-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-07-2018
Public Assessment Report Public Assessment Report Lithuanian 27-07-2018
Patient Information leaflet Patient Information leaflet Hungarian 27-07-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 27-07-2018
Public Assessment Report Public Assessment Report Hungarian 27-07-2018
Patient Information leaflet Patient Information leaflet Maltese 27-07-2018
Public Assessment Report Public Assessment Report Maltese 27-07-2018
Patient Information leaflet Patient Information leaflet Dutch 27-07-2018
Public Assessment Report Public Assessment Report Dutch 27-07-2018
Patient Information leaflet Patient Information leaflet Polish 27-07-2018
Public Assessment Report Public Assessment Report Polish 27-07-2018
Patient Information leaflet Patient Information leaflet Portuguese 27-07-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 27-07-2018
Public Assessment Report Public Assessment Report Portuguese 27-07-2018
Patient Information leaflet Patient Information leaflet Romanian 27-07-2018
Public Assessment Report Public Assessment Report Romanian 27-07-2018
Patient Information leaflet Patient Information leaflet Slovak 27-07-2018
Public Assessment Report Public Assessment Report Slovak 27-07-2018
Patient Information leaflet Patient Information leaflet Finnish 27-07-2018
Public Assessment Report Public Assessment Report Finnish 27-07-2018
Patient Information leaflet Patient Information leaflet Swedish 27-07-2018
Public Assessment Report Public Assessment Report Swedish 27-07-2018
Patient Information leaflet Patient Information leaflet Norwegian 27-07-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 27-07-2018
Patient Information leaflet Patient Information leaflet Icelandic 27-07-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 27-07-2018
Patient Information leaflet Patient Information leaflet Croatian 27-07-2018
Public Assessment Report Public Assessment Report Croatian 27-07-2018

View documents history